UBS raised the firm’s price target on Cencora (COR) to $415 from $380 and keeps a Buy rating on the shares. The initial guidance for the U.S. Healthcare Solutions segment EBIT is doable, if not conservative, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora’s Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target
- Cencora price target raised to $400 from $340 at Evercore ISI
- Cencora price target raised to $395 from $355 at Baird
- Cencora price target raised to $380 from $340 at Mizuho
- Cencora, Inc. Reports Strong Fiscal 2025 Results